139 related articles for article (PubMed ID: 14678081)
1. Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women.
Steinwall M; Bossmar T; Gaud C; Akerlund M
Acta Obstet Gynecol Scand; 2004 Jan; 83(1):12-8. PubMed ID: 14678081
[TBL] [Abstract][Full Text] [Related]
2. Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions.
Bossmar T; Brouard R; Döberl A; Akerlund M
Br J Obstet Gynaecol; 1997 Apr; 104(4):471-7. PubMed ID: 9141585
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
[TBL] [Abstract][Full Text] [Related]
4. Receptor-mediated uterine effects of vasopressin and oxytocin in nonpregnant women.
Bossmar T; Akerlund M; Szamatowicz J; Laudanski T; Fantoni G; Maggi M
Br J Obstet Gynaecol; 1995 Nov; 102(11):907-12. PubMed ID: 8534628
[TBL] [Abstract][Full Text] [Related]
5. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
Akerlund M; Bossmar T; Brouard R; Kostrzewska A; Laudanski T; Lemancewicz A; Serradeil-Le Gal C; Steinwall M
Br J Obstet Gynaecol; 1999 Oct; 106(10):1047-53. PubMed ID: 10519430
[TBL] [Abstract][Full Text] [Related]
6. The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor.
Steinwall M; Bossmar T; Brouard R; Laudanski T; Olofsson P; Urban R; Wolff K; Le-Fur G; Akerlund M
Gynecol Endocrinol; 2005 Feb; 20(2):104-9. PubMed ID: 15823830
[TBL] [Abstract][Full Text] [Related]
7. The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists.
Chan WY; Wo NC; Manning M
Am J Obstet Gynecol; 1996 Nov; 175(5):1331-5. PubMed ID: 8942510
[TBL] [Abstract][Full Text] [Related]
8. Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V1A receptors.
Chen YL; Shepherd C; Spinelli W; Lai FM
Eur J Pharmacol; 1999 Jul; 376(1-2):45-51. PubMed ID: 10440088
[TBL] [Abstract][Full Text] [Related]
9. Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea.
Liedman R; Grant L; Igidbashian S; James I; McLeod A; Skillern L; Akerlund M
Acta Obstet Gynecol Scand; 2006; 85(2):207-11. PubMed ID: 16532916
[TBL] [Abstract][Full Text] [Related]
10. ONO-8815Ly, an EP2 agonist that markedly inhibits uterine contractions in women.
Steinwall M; Akerlund M; Bossmar T; Nishii M; Wright M
BJOG; 2004 Feb; 111(2):120-4. PubMed ID: 14723748
[TBL] [Abstract][Full Text] [Related]
11. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea.
Akerlund M; Melin P; Maggi M
Adv Exp Med Biol; 1995; 395():595-600. PubMed ID: 8714023
[TBL] [Abstract][Full Text] [Related]
12. Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and a synthetic antagonist.
Hauksson A; Akerlund M; Melin P
Br J Obstet Gynaecol; 1988 Sep; 95(9):898-904. PubMed ID: 3191063
[TBL] [Abstract][Full Text] [Related]
13. Oxytocin and vasopressin V(1A) receptors as new therapeutic targets in assisted reproduction.
Pierzynski P
Reprod Biomed Online; 2011 Jan; 22(1):9-16. PubMed ID: 21130036
[TBL] [Abstract][Full Text] [Related]
14. Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans.
Weber R; Pechère-Bertschi A; Hayoz D; Gerc V; Brouard R; Lahmy JP; Brunner HR; Burnier M
Hypertension; 1997 Nov; 30(5):1121-7. PubMed ID: 9369265
[TBL] [Abstract][Full Text] [Related]
15. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.
Serradeil-Le Gal C; Herbert JM; Delisee C; Schaeffer P; Raufaste D; Garcia C; Dol F; Marty E; Maffrand JP; Le Fur G
Am J Physiol; 1995 Jan; 268(1 Pt 2):H404-10. PubMed ID: 7840290
[TBL] [Abstract][Full Text] [Related]
16. Fibromyomas and uterine contractions.
Szamatowicz J; Laudanski T; Bulkszas B; Akerlund M
Acta Obstet Gynecol Scand; 1997 Nov; 76(10):973-6. PubMed ID: 9435739
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
Cirillo R; Gillio Tos E; Schwarz MK; Quattropani A; Scheer A; Missotten M; Dorbais J; Nichols A; Borrelli F; Giachetti C; Golzio L; Marinelli P; Thomas RJ; Chevillard C; Laurent F; Portet K; Barberis C; Chollet A
J Pharmacol Exp Ther; 2003 Jul; 306(1):253-61. PubMed ID: 12660315
[TBL] [Abstract][Full Text] [Related]
18. Effect of the non-peptide, vasopressin V1a receptor antagonist, SR 49059 and its enantiomer, SR 49770, on isolated human myometrium.
Bossmar T; Rasmussen T; Akerlund M
Acta Obstet Gynecol Scand; 1996 Jul; 75(6):516-9. PubMed ID: 8693925
[TBL] [Abstract][Full Text] [Related]
19. Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea.
Brouard R; Bossmar T; Fournié-Lloret D; Chassard D; Akerlund M
BJOG; 2000 May; 107(5):614-9. PubMed ID: 10826575
[TBL] [Abstract][Full Text] [Related]
20. Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea.
Akerlund M
Prog Brain Res; 2002; 139():359-65. PubMed ID: 12436949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
